Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting.

Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting. Patients also receive a Fitbit to monitor step count

Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and walking in the postoperative setting. Patients also receive a Fitbit device, install and use the Fitbit app on a smartphone. Postoperative step goals are as follows: Postoperative day (POD) 1: 25% of baseline. Subsequent days will be increased by 10% until patient reaches baseline daily step number. Five automatic daily reminders (delivered by the Fitbit Inspire HR\^TM device itself) to meet a minimum of 250 steps an hour. Postoperatively, patients will be invited to participate in a private group with a leaderboard that consists of step numbers of other participants in the study in an anonymous fashion.

Best Practice

Health Promotion and Education

Medical Device Usage and Evaluation

Quality-of-Life Assessment

Questionnaire Administration

Garrett L Walsh

Garrett L. Walsh

This clinical trial evaluates the relationship between walking and sleeping habits and surgical outcomes in patients with lung cancer. Early walking after surgery is associated with decreased or less severe complications. Learning about how much patients walk may be important in improving outcomes after surgery. Information gained from this trial may help researchers develop interventions to improve outcomes after surgery and improve overall quality of life after surgery in patients with lung cancer.

PRIMARY OBJECTIVE:

I. Estimate the difference between each Fitbit arm and a control arm in Clavien-Dindo Combined Postoperative Morbidity (POM) Score in the 30-day postoperative period.

SECONDARY OBJECTIVES:

I. For patients in Fitbit only arm (F0) and Fitbit integration arm (FB), evaluate the differences in steps regained at each postoperative day.

II. Quality of life before and after surgery using MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC).

III. Hospital length of stay. IV. Hospital readmission rate within 30 days for lung surgery related events. V. Return of bowel function. VI. Postoperative complications and step numbers. VII. Fitbit user experience in the FB arm.

EXPLORATORY OBJECTIVES:

I. Sleep disturbances. II. Cost analysis.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting.

ARM II: Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting. Patients also receive a Fitbit to monitor step count.

ARM III: Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and walking in the postoperative setting. Patients also receive a Fitbit device install and use the Fitbit app on a smartphone. Postoperative step goals are as follows: Postoperative day (POD) 1: 25% of baseline. Subsequent days will be increased by 10% until patient reaches baseline daily step number. Five automatic daily reminders (delivered by the Fitbit Inspire HR\^TM device itself) to meet a minimum of 250 steps an hour. Postoperatively, patients will be invited to participate in a private group with a leaderboard that consists of step numbers of other participants in the study in an anonymous fashion.

After completion of study intervention, patients are followed up at postoperative clinic and at 30 days after surgery.

Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study

Ambulation to Improve Recovery With Wearable TECHnology (AIRTECH) Study

Two Bayesian probability and inferential models will be utilized:

* Model 1: Inferential goals: Probability that POM score in the control arm is greater than F0 or FB arm: mean and 95% Credible Interval
* Model 2: Baseline covariates adjusted analysis of model 1

  * Performance status
  * FEV1
  * Age
  * Open vs. Minimally invasive (0 is best, 5 is worst.) 0 - No postoperative complications 1. - Minor complication resolved without intervention 2. - complication requiring pharmaceutical intervention 3. - complication requiring surgical, endoscopic or radiological intervention, 4. - life-threatening complication requiring intensive care 5. - complication leading to the patient's death.

Number of steps regained starting from after surgery for each of the arms.

Assessed using MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC). (0 - 10 discrete numbers) 0 - Not present 10 - As bad as you can imagine.

How would you rate daily step goals as being helpful in your postoperative recovery? From 0-5, 0 being not helpful at all and 5 being the most helpful.

Survey. How would you rate the use of Fitbit in your postoperative recovery From 0-5, 0 being not helpful at all and 5 being the most helpful How difficult was it to keep the device on your wrist From 0-5, 0 being extremely difficult, and 5 being extremely easy.

M.D. Anderson Cancer Center

The research intervention is, for all twenty patients, to wear a smart t-shirt connected to a smart phone throughout the day (preferably 8 hours pr day) for 2 weeks.

The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.

Wearable sensor

Cecilie Holländer-Mieritz, MD

The study will assess the feasibility of using the ChronolifeTM smart t-shirt for home monitoring of vital parameters in cancer patients during their treatment course. This study will bring new insights to how wearables and biometric data can be used as a part of symptom recognition in cancer patients during treatment course in the quest of increasing patients' quality of life.

Collecting biometric sensor data by wearables is an example of real-time patient-generated health data that can provide vital and detailed objective information about patients. This may have the potential to improve quality of oncological treatment and increase patients' quality of life.

Studies have shown that there may be a dissimilar perception on symptoms and side effects between patients and health care professionals. Wearables may help identifying symptoms earlier.

A new design of a wearable is a smart t-shirt. A smart t-shirt has sensors embedded in the fabric which generate measurement flows. This new tool provide more precise information without recall and reporting bias which may have the potential to lead to a better and more accurate cancer treatment.

Feasibility of Monitoring Cancer Patients With a Smart T-shirt: Protocol for the OncoSmartShirt Study

Changes in heart rate (beat per minute) will be presented descriptively.

Changes in skin temperature (°C) will be presented descriptively.

Changes in physical activity (steps) will be presented descriptively.

Changes in respirations frequency (respiration per minute) will be presented descriptively.

Changes in thoracic impedance (kOhm) will be presented descriptively.

To assess the feasibility of using the ChronolifeTM smart t-shirt based on the completion rate which is defined as the number of included patients using the smart t-shirt at least 12 hours pr. day during the three weeks study period.

To assess technical feasibility in a Danish healthcare system including data acquisition rate and data completeness.

Rigshospitalet, Denmark

Professor, MD

Patients with cancer referred for systemic treatment of the outpatient clinic at the departments of Medical Oncology at participating centres.

Laurien Buffart, PhD

Calvin Brouwer, Msc

Joeri Douma, MD

Joeri Douma, PhD

Evelien Kuip, MD

Laurien Buffart

Leni van Doorn

Verheul Henk, Prof

The goal of this observational study is to investigate whether daily physical activities measured with a smartphone are related to the possible side effects or other physical complaints that arise as a result of cancer treatment. The investigators want to test whether the number of steps per day, both before and during treatment, are related to possible side effects or other physical complaints of the treatment using a smartphone. Knowledge about this relationship gives us possible starting points to prevent and/or reduce side effects and improve treatment outcomes. Additional research would then be needed.

The investigators also want to investigate whether these daily measurements are feasible for patients undergoing treatment.

Participation in the study involves measuring daily physical activity from the week before treatment until the first 3 months of treatment have been completed. This is done by tracking daily steps with patients own phone using the OncoSTAPP application.

Rationale: Systemic treatment of patients with cancer has a multimodal approach with the goal of balancing quantity and quality of life. Treatment decisions are influenced by tumour and patient-related characteristics. Additionally, in clinical practice performance status is used to identify whether a patient is sufficiently fit for systemic treatment, as it has shown to be a valid prognostic factor for survival and adverse events during treatment. However, treatment-related toxicities and hospitalisations occur frequently during systemic treatment.

The disadvantages of performance status assessed with ECOG or Karnofsky, is that it is a subjective measurement which is prone to bias and has high interobserver variability. Also a patient's self-reported physical function is significantly associated with shorter (progression-free) survival, but it is also subjective and is prone to multiple forms of bias. Objective assessment of physical function might be a good alternative to counteract these shortcomings. A higher level of physical activity is associated with a reduction in cancer specific mortality and can be measured with accelerometers, pedometers or multisenor systems like smartphones.

Wearable measured step count assessed with a wrist worn device provided by the investigators has shown to be associated with adverse events. However, these devices cannot be provided to all patients in clinical practice.

Recently, the investigators showed that the smartphones' assessments of physical activity (step count), have excellent agreement with accelerometer assessments of physical activity and good test-retest reliability. Furthermore this smartphone measurements were associated with early trial discontinuation in phase 1/2 cancer trials.

The investigators hypothesize that a low baseline and/or a reduction in physical activity (step count) measured with smartphones will be predictive for clinically relevant adverse events during systemic treatment. Adding objective information of physical function in the process of selecting the best treatment for a patient may help prevent unnecessary adverse events. Additionally, a detection of a decline in physical activity during treatment may identify upcoming adverse events early, allowing timely management/support. This may help to optimize treatment and quality of life.

Objective: Primary objectives: 1) To determine whether baseline physical activity, measured by the number of steps per day with a smartphone, is associated with clinically relevant adverse events during treatment.

2) To determine whether changes in physical activity, measured by the number of steps per day with a smartphone, are associated with clinically relevant adverse events during treatment.

Clinically relevant adverse events during treatment are defined as hospitalizations, early treatment discontinuation, relative dose intensity below 70% and mortality.

Secondary: Patients' acceptability of the application. The association of physical activity with relative dose intensity, progression free and overall survival. The association between the oncologists' estimates and clinically relevant adverse events during treatment, and the possible added value of objective assessments of physical activity.

Study design: Prospective observational cohort study.

Study population: 411 patients with cancer referred for systemic treatment at the departments of Medical Oncology at participating centres.

Intervention: N/A.

Main study parameters/endpoints: Collection of daily number of steps will start in the week before treatment and will continue for the first 3 months of systemic treatment. Mean number of steps per day will be measured passively with a smartphone application on patients' own smartphones. Primary endpoint is any clinically relevant adverse events during treatment, defined as hospitalizations, significant dose modifications of treatment and mortality.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participation in this study will not cause any additional risks or expected benefits for participants. No extra visits to the hospital will be necessary. It will provide us knowledge, which may be used in the future to better select patients for systemic treatment.

Patients will be asked to carry their smartphone on them during the duration of the study.

Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count

Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count - Prospective Cohort Study

No current plans for data sharing. Patients gave informed consent to share data with studies in line with the current research question. Data availible on request.

Comorbidities of the patiënt, with the Charlson Comorbidity Index (CCI)

tumour type and stage, pathology findings.

previous treatments related to current tumour. including surgery, radiotherapy and all systemic treatments

treatment characteristics, type of systemic treatment

Total number of medications before current systemic treatment.

laboratory finding captured as routine care at enrolement, Hemoglobin (mmol/L)

laboratory finding captured as routine care at enrolement, Leukocytes (10\*\*09/L)

laboratory finding captured as routine care at enrolement, Trombocytes (10\*\*09/L)

laboratory finding captured as routine care at enrolement, Neutrophils (10\*\*09/L)

laboratory finding captured as routine care at enrolement, Lymphocytes (10\*\*09/L)

laboratory finding captured as routine care at enrolement, Sodium (mmol/L)

laboratory finding captured as routine care at enrolement, Urea (mmol/L)

laboratory finding captured as routine care at enrolement, Creatinine (umol/L)

laboratory finding captured as routine care at enrolement, Creatinine clearance (ml/min/1.73m2) CKD-EPI-GFR

laboratory finding captured as routine care at enrolement, alanine aminotransferase (U/L) (ALAT)

laboratory finding captured as routine care at enrolement, Aspartate aminotransferase (U/L) (ASAT)

laboratory finding captured as routine care at enrolement, Serum Lactate Dehydrogenase (U/L) (LDH)

laboratory finding captured as routine care at enrolement, Alkaline phosphatase (U/L)

laboratory finding captured as routine care at enrolement, Serum Albumin (g/L)

laboratory finding captured as routine care at enrolement, C-reactive protein (mg/L)

Mean number of steps per day measured with a smartphone. At baseline and during treatment

Hospitalizations during treatment related to the therapy; will be combined into Clinically relevant adverse events during treatment

Early treatment discontinuation, within the first 3 months; will be combined into Clinically relevant adverse events during treatment

Relative dose intensity (RDI) below 70%; will be combined into Clinically relevant adverse events during treatment

Mortality due to treatment toxicity; will be combined into Clinically relevant adverse events during treatment

The percentage of planted dose and time between doses will be retrieved form patients' medical records (EPIC). The RDI will be calculated by total percentage of given dose divided by the proportion of the actual time in relation to the standard time. RDI=(Total percentage of given dose)/((Actual time)/(Standard time))\*100

The Eastern Cooperative Oncology Group/World Health Organization Performance Status (ECOG/WHO-PS) will be determined by the treating physician before treatment as stated in the current treatment guidelines of the departments of Medical Oncology. scale 0 to 5, with 0 denoting perfect health and 5 death.

Question if patients are defined as at high (\>50%) or low risk of dose limiting (\>25% or discontinuation) toxicity during the first 3 months of systemic treatment. This will be documented in patients' medical records (e.g. EPIC).

Overall survival is defined as the time between start of trial participation and death of any cause and will be tracked via the patients' medical records (e.g. EPIC).

Progression free survival is defined as the time between start of systemic treatment and the clinically or radiologically confirmation of progressive disease (established via RECIST-criteria) and will be tracked via the patients' medical records (e.g. EPIC).

Validity of the smartphone application will be assesed by the proportion of patients correctly collected the data.

A consecutive sample of patients will be contacted for a short interview about the use of the smartphone application, until data saturation. Any spontaneously reported reactions about the smartphone application will be collected.

Erasmus Medical Center

Medisch Centrum Leeuwarden

Radboud University Medical Center

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)

Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)

Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior

Narrative visualization

Participants self-monitor steps using a wearable device, app, and a hand-written step log

Standard self-regulation

Elizabeth J Lyons, PhD, MPH

This study tests the feasibility and acceptability of a physical activity intervention that combines use of a wearable activity monitor with a scrapbook. Half of the participants will receive this enhanced intervention, while the other half will receive a wearable activity monitor with a standard step log.

Women breast cancer survivors could benefit from increased physical activity but are in need of greater motivation to be active. Interventions that use wearable activity monitors and mobile apps have shown promise in the short-term, but use drops off over time. Reports have suggested that users find the step data provided to be unclear and not very personally meaningful. The ultimate purpose of this line of research is to test whether enhanced motivational feedback, using scrapbooks, can increase motivation for activity. The scrapbooks will target integrated regulation, which is a type of motivation related to personal identity and values. Participants who receive this intervention will draw their step graph, add photographs and stickers an explanations to the graph, and answer reflection questions daily. Before testing the effects of this intervention on physical activity, the investigators must first ensure that the materials and procedures are feasible and acceptable. This small pilot study will allow the research team to iteratively test scrapbook materials and improve upon them for use in future studies. The investigators will compare an intervention using the enhanced materials to an intervention using only the wearable device, app, and a standard step log without scrapbook or reflection components. In addition to the primary outcome of feasibility (use of the scrapbook), the investigators will also explore the effects of the intervention on steps, motivational and values-related outcomes, and various aspects of feasibility and acceptability.

Narrative Visualization for Breast Cancer Survivors' Physical Activity

The investigators will provide access to all data, regardless of publication, collected as a part of this project. All external investigators must submit a written request identifying their research question(s) and specifying the data they would like to analyze. The request must include a data security plan and explanation of how the data will be stored and who will have access. All requests will be reviewed by the investigators in conjunction with UTMB's Institute for Translational Sciences key resources (in particular, the regulatory and ethics resources) to be sure appropriate NIH requirements are followed.

Self-reported percent of study materials received out of total supplied

Self-reported usefulness of study materials, on a scale from 1 (strongly disagree they were useful) to 5 (strongly agree they were useful)

Number of participants in each group who are lost to follow-up

The number of serious adverse events that occur during the intervention (0 - 12 weeks) and follow-up period (12 - 24 weeks)

The number of days the activity monitor was worn, as assessed via review of the mobile app

From photographs taken of the intervention materials at the 12 week assessment, the investigators will assess whether participants in the enhanced intervention group completed their values clarification activity

Percentage of daily workbook entries completed out of the total possible number, measured by photography of intervention materials at 12 week assessment and then assessment of each page.

Mean of daily steps taken from accelerometers worn for 7 days

Mean of steps per day taken from accelerometers worn for 7 days

Self-reported intrinsic regulation on a scale from 0 (least motivated) to 4 (most motivated) using the Behavioral Regulation in Exercise Questionnaire - 3. Reported here are results from the intrinsic regulation subscale. Higher results on the scale indicate greater intrinsic regulation.

Self-reported integrated regulation on a scale from 0 (least motivated) to 4 (most motivated) using the Behavioral Regulation in Exercise Questionnaire - 3. Here, results from the integrated regulation subscale are reported. Higher numbers on the scale indicate greater integrated regulation.

Self-reported fulfillment of basic psychological needs on a scale from 1 (least fulfilled) to 5 (most fulfilled) using the Basic Psychological Needs in Exercise Questionnaire. The three subscales are perceived autonomy, competence, and relatedness. Here, autonomy is reported. A higher score means greater perceived autonomy.

Self-reported identity as an exerciser on a scale from 1 (strongly disagree) to 7 (strongly agree) as measured by the Exercise Identity Scale. The two subscales are exercise beliefs and exercise role identity. Here, exercise role identity is reported. A higher score means greater exercise role identity.

Self-reported fulfillment of basic psychological needs on a scale from 1 (least fulfilled) to 5 (most fulfilled) using the Basic Psychological Needs in Exercise Questionnaire. The three subscales are perceived autonomy, competence, and relatedness. Here, competence is reported. A higher score means greater perceived competence.

Self-reported fulfillment of basic psychological needs on a scale from 1 (least fulfilled) to 5 (most fulfilled) using the Basic Psychological Needs in Exercise Questionnaire. The three subscales are perceived autonomy, competence, and relatedness. Here, relatedness is reported. A higher score means greater perceived relatedness.

Self-reported self-reflection on a scale from 1 (strongly disagree) to 5 (strongly agree) using the Self-Reflection and Insight Scale. Here, we report changes in the insight subscale, which has 8 items and a range of 5-40. For this scale, higher values indicate greater levels of insight.

Self-reported quality of life on a scale from 0 (not at all) to 4 (very much) using the Functional Assessment of Cancer Therapy - Breast measure. Reported here is the change in total score for the entire measure (with the total ranging from 0-123). Better quality of life is indicated by a lower score.

Self-reported importance of family, intimate relationships, friends, work, health, and growth values domains on a scale from 0 (not at all important) to 5 (extremely important) using the Chronic Pain Values Inventory. Reported here is the change in total across all domains, which is an average of the individual items (range: 0-5). A higher score indicates stronger endorsement of importance of the valued domains.

Self-reported success in living according to values related to family, intimate relations, friends, work, health, and growth on a scale from 0 (not at all successful) to 5 (extremely successful) using the Chronic Pain Values Inventory. Reported here is the change in total across all domains, as an average across items (range: 0-5). A higher score indicates stronger endorsement of success in the valued domains.

Self-reported perception of living in accordance with one's values on a scale from 1 (completely disagree) to 5 (completely agree) using the Engaged Living Scale. The two subscales are valued living and life fulfillment. Reported here is the change in total results for the scale (which ranges from 16-80). Higher scores on this scale indicate higher levels of engaged living.

National Cancer Institute (NCI)

The University of Texas Medical Branch, Galveston

Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)

Narrative visualization: Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior

Narrative Visualization

Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)

Standard self-regulation: Participants self-monitor steps using a wearable device, app, and a hand-written step log

Standard Self-regulation

Total

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Missing data were imputed except for 3 participants with data missing at baseline. Results should be interpreted with caution due to the pilot nature of the trial and data collection occurring partially during spring/summer 2020.

Several outcomes (valued and engaged living, quality of life) were changed from secondary to other pre-specified, as these are likely not interpretable due to external factors (e.g., COVID-19 and social distancing).

Eloisa Martinez

This outcome was only analyzed in the intervention group

Percentage of Daily Workbook Entries Completed

Physical Activity as Measured by Steps Per Day During Intervention Period

Physical Activity as Measured by Daily Steps During No-intervention Maintenance Period

Intrinsic Regulation

Integrated Regulation

Basic Psychological Needs: Autonomy

Exercise Identity

Basic Psychological Needs: Competence

Basic Psychological Needs: Relatedness

Self-reflection

Quality of Life (Physical, Social, Emotional, Functional, and Breast Cancer-specific)

Importance of Valued Domains

Success in Living According to Valued Domains

Engaged Living

Receipt of Study Materials

Usefulness of Study Materials

Participant Attrition

Number of Serious Adverse Events

Days the Activity Monitor Was Worn

Completion of Values Clarification Activity

0 - 12 Weeks

12 - 24 Weeks

Participants will be enrolled in the experimental trial to receive Fitbits and a smartphone app.

Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.

Wearable device deployment

Jamie M Faro, PhD

The Survivor mobile health (mHealth) study is testing the use of wearable devices (Fitbits) and a smartphone application in cancer survivors. The goal of the program is to increase survivor's physical activity levels. The Fitbit will be synced to the app and participants will receive messages and notifications about their activity levels. Participants will also complete surveys through the app asking how useful it is and ways to improve it. The study team will conduct qualitative interviews at the completion of the 3 months to see how participants liked the program, and ways it can be improved and make it more specific to cancer survivors. The study team will also conduct interviews with providers and clinic staff to assess their perceptions of patient digital health programs and preferences for receiving patient-generated health data.

Survivor mHealth: Wearable Devices in Cancer Survivors

Survivor mHealth: Assessing Feasibility of a Wearable Device and App in Cancer Survivors

Qualitative feedback from providers on their preferences for patients using wearable devices and receiving patient-generated data

Feasibility will be determined by a participant meeting all three criteria: 1) Enrollment in trial, 2) completion of baseline measures, and 3) Fitbit sync to app.

Change from baseline to 3-months in steps, light, moderate and vigorous physical activity measured via Fitbits.

Change from baseline to 3-months in light, moderate and vigorous physical activity survey-measured (Godin leisure time questionnaire) physical activity. The questionnaire is a 4-item self-administered questionnaire with the first three questions seeking information on the number of times one engages in mild, moderate and strenuous leisure-time physical activity bouts of at least 15 min duration in a typical week. Scores can range from 0 to 98, with the higher score meaning a greater level of activity for that week.

The Functional Assessment of Cancer Therapy - General (FACT-G) is a 27-item questionnaire assessing physical, emotional, social, and functional well-being over the past 7 days. Participants respond on a Likert scale of 0 to 4 (0=Not at all, 4=Very much). Scores are summed to a total of 0-108 points, with a higher score indicating a greater quality of life.

Mobile Application Rating Scale (MARS). The Rating scale assesses app quality on four dimensions. All items are rated on a 5-point scale from "1.Inadequate" to "5.Excellent". A higher score indicates greater user acceptability of the app.

Qualitative feedback from enrolled participants on the acceptability of the Fitbits, app, mobile questionnaires, and push notification messages within the app

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study	NCT04783168	Lung Carcinoma	Best Practice Health Promotio... Medical Device ... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Feasibility of Monitoring Cancer Patients With a Smart T-shirt: Protocol for the OncoSmartShirt Study	NCT05235594	Cancer	Wearable sensor	18 Years -	Rigshospitalet, Denmark
Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count	NCT05927636	Cancer Systemic Treatm... Physical Activi... Toxicity Due to...		18 Years -	Radboud University Medical Center
Narrative Visualization for Breast Cancer Survivors' Physical Activity	NCT03612596	Breast Cancer	Narrative visua... Standard self-r...	55 Years - 79 Years	The University of Texas Medical Branch, Galveston
Survivor mHealth: Wearable Devices in Cancer Survivors	NCT05417438	Cancer Cardiovascular ...	Wearable device...	18 Years - 100 Years	University of Massachusetts, Worcester
Survivor mHealth: Wearable Devices in Cancer Survivors	NCT05417438	Cancer Cardiovascular ...	Wearable device...	18 Years - 100 Years	University of Massachusetts, Worcester
Survivor mHealth: Wearable Devices in Cancer Survivors	NCT05417438	Cancer Cardiovascular ...	Wearable device...	18 Years - 100 Years	University of Massachusetts, Worcester
Narrative Visualization for Breast Cancer Survivors' Physical Activity	NCT03612596	Breast Cancer	Narrative visua... Standard self-r...	55 Years - 79 Years	The University of Texas Medical Branch, Galveston
Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count	NCT05927636	Cancer Systemic Treatm... Physical Activi... Toxicity Due to...		18 Years -	Radboud University Medical Center

Spots Global Cancer Trial Database for wearable

Every month we try and update this database with for wearable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for wearable

Every month we try and update this database with for wearable cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for wearable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.